Becton, Dickinson and Company (NYSE:BDX) Plans $1.05 Quarterly Dividend

Becton, Dickinson and Company (NYSE:BDX) announced a quarterly dividend on Tuesday, July 28th. Shareholders of record on Wednesday, September 9th will be paid a dividend of 1.05 per share by the medical instruments supplier on Wednesday, September 30th. This represents a c) annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, September 9th.

Becton, Dickinson and Company has raised its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 53 years. Becton, Dickinson and Company has a dividend payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Becton, Dickinson and Company to earn $13.48 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 31.2%.

Becton, Dickinson and Company Stock Performance

BDX stock traded up $2.21 during trading on Wednesday, reaching $168.55. 131,919 shares of the company’s stock were exchanged, compared to its average volume of 2,725,226. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The firm has a market cap of $46.44 billion, a PE ratio of 42.65, a P/E/G ratio of 11.24 and a beta of 0.21. The company’s fifty day moving average price is $150.67 and its 200-day moving average price is $164.15. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same period last year, the company earned $3.35 earnings per share. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.